AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $289.18, with a market capitalization of 510.63B. The stock trades at a price-to-earnings (P/E) ratio of 79.93 and offers a dividend yield of 2.42%.
On 2026-10-20, AbbVie(ABBV) stock traded between a low of $284.88 and a high of $290.98. Shares are currently priced at $289.18, which is +1.5% above the low and -0.6% below the high.
AbbVie(ABBV) shares are trading with a volume of 5.17M, against a daily average of 5.56M.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $291.40 at its peak.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $291.40 at its peak.
ABBV News
AbbVie (NYSE:ABBV) reported new clinical data for dual-targeting Crohn’s therapy ABBV-466, showing higher endoscopic remission rates than current monotherapies....
Kevin Warsh's Federal Open Market Committee (FOMC) has its next meeting on Oct. 28 to decide on a course of action for interest rates. It looks as if they aren'...
AbbVie (ABBV) and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 T...
Analyst ratings
75%
of 32 ratingsMore ABBV News
AbbVie (ABBV) announced that its investigational ABBV-466, a dual-targeting therapy against IL-23 p19 and integrin a4ss7, demonstrated higher rates of endoscopi...
AbbVie (ABBV) announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology, ESMO...
AbbVie (ABBV) announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology, UEG, Week, October...
Not all high-yield dividend stocks are created equal. Some are genuine income compounders, while others are traps. And the current environment, with interest ra...
AbbVie (ABBV +0.71%), which accounts for 6.2% of my portfolio, is one of my favorite long-term dividend stocks. The pharmaceutical giant has raised its dividend...
Biopharma stocks like AbbVie and Eli Lilly are trading at or near all-time highs, in the latest signal that investors are seeking out the steady gains that come...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie’s latest early stage study tests a new oral drug, ABBV-1042, in healthy adults to tra...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.